Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer

Figure 4 Grafical representation of bevacizumab not bevacizumab-bound vascular endothelial growth factor/total vascular endothelial growth factor before 2^nd cycle in bevacizumab treated metastatic colorectal cancer patients (A) and before 5^th cycle in partial response (B), stable disease (C) and progression disease (D) groups. BV: Bevacizumab; VEGF: Vascular endothelial growth factor; PR: Partial response; SD: Stable disease; PD: Progression disease; mCRC: Metastatic colorectal cancer.